Novartis Ag (NVS) Non-Current Deferred Tax Liability (2009 - 2026)

Novartis Ag has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $5.3 billion in Q2 2026.

• Quarterly Non-Current Deferred Tax Liability rose 128.01% year-over-year to $5.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.3 billion (up 128.01% YoY) and the FY2025 annual result came in at $3.4 billion, up 525.16% from the prior year.
• Non-Current Deferred Tax Liability climbed to $5.3 billion in Q2 2026 per NVS's latest filing, from -$2.5 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $5.3 billion in Q2 2026 and troughed at -$2.5 billion in Q1 2026.
• A 5-year average of $983.2 million and a median of -$3.0 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability plunged 877.42% in 2022, then surged 933.66% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $2.7 billion in 2022, then plunged by 117.65% to -$474.0 million in 2023, then sank by 68.57% to -$799.0 million in 2024, then soared by 525.16% to $3.4 billion in 2025, then soared by 55.78% to $5.3 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $5.3 billion, -$2.5 billion, and $3.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.